ALXO - ALX Oncology ties up with Tallac in cancer immunotherapeutics push

ALX Oncology (ALXO) and privately held Tallac Therapeutics announce collaboration to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics.Under the terms of the agreement, the companies will share equally in the cost of research and development and any profits or losses incurred.The collaboration builds on ALX oncology’s expertise in developing therapies that block the CD47 checkpoint pathway and expands its immuno-oncology pipeline.The companies will leverage their respective scientific and technical expertise to advance an anti-SIRP? antibody conjugated to a Toll-like receptor 9 (“TLR9”) agonist for targeted activation of both the innate and adaptive immune systems.ALX Oncology and Tallac will host a conference call on Friday at 8:30 a.m. EST to further discuss the deal.

For further details see:

ALX Oncology ties up with Tallac in cancer immunotherapeutics push